Protocol Ledger

NCT07022223 · Phase II · RECRUITING

Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma

Interventional Phase II clinical trial protocol NCT07022223 sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-11 Enrollment: 51 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07022223
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)51 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07022223
Protocol FieldVerified Registry Value
NCT IdentifierNCT07022223
Consolidated Lead SponsorSecond Affiliated Hospital, Zhejiang University, School of Medicine
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment51 participants (ESTIMATED)
Registered Start Date2025-03-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07022223
Hospital Research SiteLocationSite Profile
Zhejiang Cancer HospitalHangzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI